Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Queensland Health
Teva
Cantor Fitzgerald
Deloitte
Citi
McKesson
Mallinckrodt
Accenture
Merck

Generated: October 22, 2017

DrugPatentWatch Database Preview

BANZEL Drug Profile

« Back to Dashboard

What is the patent landscape for Banzel, and when can generic versions of Banzel launch?

Banzel is a drug marketed by Eisai Inc and is included in two NDAs. There are three patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in BANZEL is rufinamide. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rufinamide profile page.

Summary for Tradename: BANZEL

US Patents:3
Applicants:1
NDAs:2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list66
Patent Applications: see list321
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:BANZEL at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-001Nov 14, 2008DISCNYesNo► Subscribe► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-003Nov 14, 2008ABRXYesYes► Subscribe► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-002Nov 14, 2008ABRXYesNo► Subscribe► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-003Nov 14, 2008ABRXYesYes► Subscribe► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-001Nov 14, 2008DISCNYesNo► Subscribe► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-001Nov 14, 2008DISCNYesNo► Subscribe► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-002Nov 14, 2008ABRXYesNo► Subscribe► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-002Nov 14, 2008ABRXYesNo► Subscribe► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
SUSPENSION;ORAL201367-001Mar 3, 2011RXYesYes► Subscribe► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
SUSPENSION;ORAL201367-001Mar 3, 2011RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for BANZEL

Drugname Dosage Strength RLD Submissiondate
rufinamideTablets100 mg, 200 mg and 400 mgBanzel11/14/2012
rufinamideOral Suspension40 mg/mLBanzel6/16/2014
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Boehringer Ingelheim
Argus Health
QuintilesIMS
Express Scripts
Daiichi Sankyo
Moodys
US Department of Justice
Colorcon
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot